SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against SARS-CoV-2 Delta and Omicron that can be predicted by anti-S antibody concentrations in serological assays

- Alina Seidel, MSc*1; Bernd Jahrsdörfer, MD*2; Sixten Körper, MD*2; Dan Albers MSc1; Pascal von Maltitz, 5
- MSc¹; Rebecca Müller, MD³; Ramin Lotfi, MD²; Patrick Wuchter, MD³; Harald Klüter, MD.³; Michael 6
- Schmidt, MD⁴; Jan Münch, PhD^{1§}; Hubert Schrezenmeier, MD^{2§} 7
- 9 ¹ Institute of Molecular Virology, Ulm University Medical Center, 89081, Ulm, German
- 10 ² German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, Institute and Institute for Clinical
- 11 Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-
- 12 Württemberg-Hessen and University Hospital Ulm; and Institute of Transfusion Medicine, University of Ulm
- 13 ³ Institute of Transfusion and Immunology, German Red Cross Blood Transfusion Service Baden-
- 14 Württemberg - Hessen, Medical Faculty Mannheim, Heidelberg University, Mannheim
- 15 ⁴ Institute of Transfusion Medicine and Immunohematology, German Red Cross Blood Transfusion Service Baden-
- 16 Württemberg – Hessen, Frankfurt, Germany
- *equally contributed to this manuscript. 18
- 19 § equally contributing senior authors
- 21 Short title: Neutralization of SARS-CoV-2 Omicron by sera from vaccinated convalescents
- 22 Word Counts:
- 23 Abstract: 265 words
- 24 Manuscript text: 1417 words (without abstract, legends and references)
- 25 1 Table

1

2

3

4

8

17

20

27

- 26 4 Figures
 - **Corresponding address:**
- 29 Prof.Dr.med.Hubert Schrezenmeier,
- 30 German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and Institute for Clinical
- 31 Transfusion Medicine and Immunogenetics Ulm; and Institute of Transfusion Medicine, University of Ulm.
- 32 Helmholtzstraße 10, 89081 Ulm, Germany.
- 33 h.schrezenmeier@blutspende.de
- 34 phone: +49 731 150 550
- 35 Fax: +49 731 150 500

36 ABSTRACT: 37 Background: Recent data on immune evasion of new SARS-CoV-2 variants raise concerns about antibody-based COVID-38 39 19 therapies. Therefore in this study the in-vitro neutralization capacity against SARS-CoV-2 variants 40 Wuhan D614G, Delta and Omicron in sera of convalescent individuals with and without boost by 41 vaccination was assessed. Methods and Findings: 42 43 This in-vitro study included 66 individuals with a history of SARS-CoV-2 infection, divided into subgroups 44 without (n=29) and with SARS-CoV-2 vaccination (n=37). We measured SARS-CoV-2 antibody 45 concentrations by serological assays (anti-SARS-CoV-2-QuantiVac-ELISA (IgG) and Elecsys Anti-SARS-CoV-2 S) and neutralizing titers against Wuhan D614G, Delta and Omicron in a pseudovirus neutralization 46 47 assay. Sera of the majority of unvaccinated convalescents did not effectively neutralize Delta and Omicron (4/29, 48 49 13.8% and 19/29, 65.5%, resp.). Neutralizing titers against Wuhan D614G, Delta and Omicron were 50 significantly higher in vaccinated compared to unvaccinated convalescents (p<0.0001) with 11.1, 15.3 and 51 60-fold higher geometric mean of 50%-neutralizing titers (NT50) in vaccinated compared to unvaccinated 52 convalescents. The increase in neutralizing titers was already achieved by one vaccination dose. Neutralizing titers were highest in the first 3 months after vaccination. Concentrations of anti-S antibodies 53 54 in the serological assays anti-SARS-CoV-2 QuantiVac-ELISA (IgG) and Elecsys Anti-SARS-CoV-2 S predict 55 neutralization capacity against Wuhan D614G, Delta and Omicron. While Wuhan D614G was neutralized in-vitro by Bamlanivimab, Casirivimab and Imdevimab, Omicron was resistant to these monoclonal 56 57 antibodies. 58 **Conclusions:** These findings confirm substantial immune evasion of Delta and Omicron which can be overcome by 59 60 vaccination of convalescents. This informs strategies for choosing of plasma donors in COVID-19 61 convalescent plasma programs that shall select specifically vaccinated convalescents with very high titers

62

of anti-S antibodies.

Introduction:

The B.1.1.529 variant was first reported to the World Health Organization from South Africa on 24 November 2021 (1) and has been classified as a variant of concern (VOC), named Omicron (1).

The role of passive immune therapy of COVID-19 by convalescent plasma (CCP) is still under investigation.

Data suggest efficacy of CCP in early intervention (2-6), in particular among seronegative patients and immunosuppressed patients (7-9). A significant antibody dose response has been observed in some of the CCP trials (3;4;10;11). Omicron might escape passive immune therapy since it can evade neutralization by sera from vaccinated and convalescent individuals and by monoclonal antibodies *in-vitro* (12-16) and the risk of reinfection with Omicron is higher compared to other VOC (12).

In this study, we assessed the neutralization capacity of sera from convalescents, some but not all of which were vaccinated, against the Wuhan D614G, Delta and Omicron variants. The question was whether superimmunized individuals, i.e. vaccinated convalescents, had cross-neutralization capacity against

Omicron sufficient to be considered as plasma donors for passive immune therapy.

Methods:

Serum samples from 66 individuals with SARS-CoV-2 infection (with or without SARS-CoV-2 vaccination) were analyzed by two commercially available assays according to the instructions of the manufacturer (anti-SARS-CoV-2-QuantiVac-ELISA (IgG), Euroimmun, Lübeck, Germany and Elecsys Anti-SARS-CoV-2 A, Roche, Mannheim, Germany). Samples were collected after informed consent from convalescent plasma donors (17) and vaccinees. The studies were approved by the Ethical Committee of University of Ulm and Ethical Committee II, Heidelberg University.

Preparation of pseudotyped particles

Production of rhabdoviral pseudotypes has been previously described (18). In brief, 293T cells (ATCC no. CRL-3216) were transfected with expression plasmids encoding SARS-CoV-2 spike variants Wuhan D614G (https://doi.org/10.1016/j.cell.2021.03.036), B.1.617.2 (https://doi.org/10.1126/science.abh1766), or B.1.1.529 (https://doi.org/10.1101/2021.12.12.472286) (kindly provided by Stefan Pöhlmann, Infection Biology Unit, German Primate Center, Göttingen, Germany) by Transit LT-1 (Mirus). One day after transfection, cells were inoculated with a replication-deficient vesicular stomatitis virus (VSV) vector in which the genetic information for its native glycoprotein (VSV-G) is replaced by genes encoding enhanced green fluorescent protein and firefly luciferase (FLuc) (kindly provided by Gert Zimmer, Institute of Virology and Immunology, Mittelhäusern, Switzerland), and incubated for 2 h at 37°C. Then the inoculum was removed, cells were washed with PBS and fresh medium containing anti-VSV-G antibody (I1-hybridoma cells; ATCC no. CRL-2700) added to block remaining VSV-G carrying particles. After 16-18 h, supernatants were collected and centrifuged (2,000 x g, 10 min, room temperature) to clear cellular debris. Samples were then aliquoted and stored at -80°C.

Pseudovirus Neutralization Assay:

The pseudovirus neutralization experiments were performed as previously described (18) In brief, Vero E6 cells were seeded in 96-well plates one day prior (6,000 cells/well, 2.5% FCS. Heat-inactivated (56°C, 30 min) sera were serially titrated (4-fold titration series with 7 steps + buffer only control) in PBS,

perpetuity.

It is made available under a CC-BY 4.0 International license .

Kaysville, Utah, USA, ncss.com/software/ncss.

pseudovirus stocks added (1:1, v/v) and the mixtures incubated for 30 min at 37°C before being added to cells in duplicates (final on-cell dilution of sera: 20, 80, 320, 1,280, 5,120, 20,480, 81,920-fold). After an incubation period of 16-18 h, transduction efficiency was analyzed. For this, the supernatant was removed, and cells were lysed by incubation with Cell Culture Lysis Reagent (Promega) at room temperature. Lysates were then transferred into white 96-well plates and luciferase activity was measured using a commercially available substrate (Luciferase Assay System, Promega) and a plate luminometer (Orion II Microplate Luminometer, Berthold). For analysis of raw values (RLU/s), background signal of untreated cells was subtracted and values normalized to cells inoculated with pseudovirus preincubated with PBS only. Results are given as serum dilution on cell resulting in 50% pseudovirus neutralization (NT50), calculated by nonlinear regression ([Inhibitor] vs. normalized response — Variable slope) in GraphPad Prism Version 9.1.1. For quantitative analyses, NT50 values <20 were set to a value of 10.

The other statistical analyses were performed using GraphPad Prism Version 9.0.2, GraphPad Software, San Diego, California USA, www.graphpad.comand NCSS 2021 Statistical Software (2021). NCSS, LLC.

Results:

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

We studied a cohort of 66 individuals with a history of a SARS-CoV-2 infection (Table 1). The cohort has been subdivided in a group without vaccination (n=29) and a group with vaccination (n=37). Non-vaccinated individuals with a history of infection exhibited Wuhan D614G neutralizing titers of 249 (geometric mean neutralizing (GMN) titers, 95% confidence interval (95%-CI) 162-381) (Fig.1A). Neutralization of Delta and Omicron was undetectable (i.e. below a titer of 20) in 4/29 (13.8%) and 19/29 (65.5%) of convalescent individuals with GMN titers of 55 (35-88) and 20 (13-32)(p=0.0021 compared to Wuhan D614G). However, convalescents who had received at least one vaccination dose exhibited significantly higher neutralizing titers compared to non-vaccinated convalescents: 2761 (1763-4323) against Wuhan D614G, 841 (545-1300) against Delta and 1204 (634-2284) against Omicron (Fig.1A). Folddifference in GMN titers of vaccinated convalescents versus non-vaccinated convalescents is 11.1-fold for Wuhan D614G, 15.3-fold for Delta and 60-fold for Omicron (Fig.1A). Neutralizing titers against Wuhan D614G and Omicron did no longer differ significantly in convalescents after vaccination (Fig.1A). For all three variants, neutralizing titers were not significantly different between subjects who received either one or two vaccinations, resp. (Fig.1B). Neutralizing titers against Wuhan D614G and Delta were significantly higher among those with an interval ≤ 90 days since the last vaccination dose as compared to intervals >90 days, while for Omicron no such significant difference was found (Fig.1C). The geometric means of NT50 against Wuhan D614G were 4741 (≤90 days) and 1644 (>90 days)(p=0.0326), against Delta 1496 (≤90 days)) and 501 (>90 days)(p=0.0202), and against Omicron 1953 (≤90 days)) and 843 (>90 days)(p=0.1352). While in the pseudovirus neutralization assay Omicron was neutralized in-vitro by the polyvalent antibodies of convalescent, vaccinated individuals (Fig.1A), it was resistant to the monoclonal antibodies Bamlanivimab, Casirivimab and Imdevimab (Fig.1D). The correlation matrix of NT50 against Wuhan D614G, Delta and Omicron, the -QuantiVac-ELISA (IgG) ELISA and the Elecsys Anti-SARS-CoV-2 S revealed good correlations between all five assays, in particular between the two anti-SARS-CoV-2 serological assays (Spearman correlation 0.95) and the NT50 against

Wuhan D614G and Delta (Spearman correlation 0.93)(Fig.2). Spearman correlation between anti-SARS-

CoV-2-QuantiVac-ELISA (IgG) and NT50 against Omicron or Delta was 0.88 and 0.94 (Fig.3A and Fig.3C). The Spearman correlation between Elecsys Anti-SARS-CoV-2 S and NT50 against Omicron and Delta was 0.92 and 0.90 (Fig.3B and Fig.3D). Plasma units for immune therapy shall have very high neutralizing titers - we assumed NT50≥640. Receiver operating characteristics (ROC) demonstrate that both anti-SARS-CoV-2-QuantiVac-ELISA- (IgG) and Elecsys anti-SARS-CoV-2 S excellently predict these neutralizing titers with areas under the curve between 0.94 and 0.95 for anti-SARS-CoV-2-QuantiVac-ELISA (IgG) and between 0.95 and 0.98 for Elecsys Anti-SARS-CoV-2 S (Fig.4A-C).

142

143

144

145

146

147

148

Discussion

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

Our observations are consistent with other in-vitro studies which reported significant immune evasion by Omicron (12;13;15;16). This has raised concerns that antibody therapies may no longer be effective against Omicron. Therefore, in contrast to other recent studies on Omicron immune evasion, we focus on convalescent individuals and the implication of evasion from antibody-mediated neutralization for future CCP programs. Our data confirm in-vitro resistance of Omicron to several monoclonal antibodies used in clinical practice (13-16) questioning the efficacy in Omicron infected patients. Also, Delta and Omicron are no longer well neutralized in-vitro by sera of convalescents from the first and second surge of the SARS-CoV-2 pandemic. However, in convalescents just one dose of SARS-CoV-2 vaccination can restore in-vitro neutralization capacity against Delta and Omicron. In contrast to other recent reports on significantly lower neutralization capacity in vaccinated convalescent donors (14-16) compared to wild type, we observed a comparable neutralization capacity against Wuhan D614G and Omicron. This might be due to our high sample size, the neutralization assay, the large proportion of donors with high anti-S antibody concentration in our cohort and the vaccination scheme. Our findings suggest that even without adaption of current available vaccines, the broader immune repertoire in superimmunized individuals can cover novel variants (19), particularly in the first three months after vaccination when the highest neutralizing titers are achieved. Systematic screening of convalescent, vaccinated donors using commercially available high-throughput serological assays (Anti-SARS-CoV-2-QuantiVac-ELISA (IgG); Elecsys Anti-SARS-CoV-2 S) can identify plasma donors with very high SARS-CoV-2 antibody concentrations, who also have very high in-vitro neutralizing titers against Wuhan D614G, Delta and Omicron. Therefore, for future convalescent plasma programs, priority should be given to superimmunized donors with previous infection plus at least one dose of a SARS-CoV-2 vaccination (preferably within the last 3 months) with very high SARS-CoV-2

antibody concentrations as measured by serological assays. A concept of early, very high titer CCP from

- 175 highly selected superimmunized donors must be investigated in clinical trials (e.g. COVIC-19 trial, EudraCT
- 176 021-006621-22).

Conflicts of interest:

177

178

179

180

181

182

183

184

185

186

187

188

189

B.J., S.K., R.L., R.M., P.W., M.S., H.K. and H.S. are employees of a blood transfusion service collecting

plasma including convalescent plasma.

Acknowledgement:

The clinical trials COVIC-19 (EudraCT 021-006621-22) is supported by the Bundesministerium für Bildung und Forschung ("German Federal Ministry of Education and Research") and the randomized clinical trial CAPSID (EudraCT including the preparation of convalescent plasma units was supported by the Bundesministerium für Gesundheit ("German Federal Ministry of Health"). H.S., J.M. and H.K. acknowledge funding from the Ministry for Science, Research and the Arts of Baden-Württemberg, Germany (COVID-19 Sonderförderlinie, CORE Project). HS acknowledges funding by the European Commission (HORIZON2020 Project SUPPORT-E, no. 101015756). J.M. further acknowledges funding by

EU's Horizon 2020 research and innovation programme (Fight-nCoV, 101003555).

Table 1: Characteristics of the study cohort of convalescent individuals

	Prior history of infection	Prior history of
	no vaccination	infection
		+ vaccination
	(n=29)	(n=37)*
Median age, years (IQR)	48 (34-57)	48.5 (32.8-56)
Gender, no		
Female / male	13 / 16	26 / 11
Median interval since infection, days (IQR)	119.0 (85.0– 136.5)	387.0 (226.0 – 434.0)
No. of vaccination doses, n (%)		
0	29 (100%)	-
1	-	17 (45.9%)
2	-	20 (54.1%)
Type of vaccination, n (%)	n.a.	
BNT162b		25 (67.6)
mRNA-1273		7 (18.9)
ChAdOx1		5 (13.5)
Median interval since last vaccination	n.a.	93.0 (25.0 – 160.3)

n.a.: not applicable

191

192

190

* n=3 individuals had breakthrough infection after vaccination.






Figure 1: Neutralization of Spike variants by convalescent sera and monoclonal antibodies

- A) NT50 for in-vitro neutralization of Wuhan D614G (blue symbols), Delta (green symbols) and Omicron (red symbols) for individuals with a history of infection (inf)(lighter colors)(n=29) and history of infection and vaccination (inf + vax, darker colors)(n=37). The p-values for the pairwise comparisons shown above the graph were calculated by Kruskal-Wallis Test followed by Dunn's test for correction for multiple comparisons. The horizontal black lines denote the geometric mean of NT50 and the error bars the 95%-confidence interval of the geometric mean. Fold-increase in geometric mean NT50 of vaccinated convalescents versus non-vaccinated convalescents is 11.1-fold for Wuhan D614G, 15.3-fold for Delta and 60-fold for Omicron.
- B) NT50 for in-vitro neutralization of Wuhan D614G (blue symbols), Delta (green symbols) and Omicron (red symbols) for vaccinated, convalescent donors stratified by number of vaccination doses: 1 vaccination dose (1 vax)(lighter colors)(n=17) and 2 vaccination doses (2 vax)(darker colors)(n=20). The p-values for the pairwise comparisons were calculated by Kruskal-Wallis Test. The horizontal black lines denote the geometric mean of NT50 and the error bars the 95%-confidence interval of the geometric mean. The geometric means of NT50 were as follows: against Wuhan D614G 4102 (1 vax) and 1972 (2 vax), against Delta 1038 (1 vax) and .704 (2 vax), against Omicron 160 (1 vax) and 943 (2 vax).
- C) NT50 for in-vitro neutralization of Wuhan D614G (blue symbols), Delta (green symbols) and Omicron (red symbols) for vaccinated, convalescent donors stratified by interval between vaccination and collection of serum sample: ≤ 90 days (lighter colors)(n=17) and >90 days (darker colors)(n=19). The p-values for the pairwise comparisons were calculated by Kruskal-Wallis Test. The horizontal black lines denote the geometric mean of NT50 and the error bars the 95%-confidence interval of the geometric mean. The geometric means of NT50 were as follows: against Wuhan D614G 4741 (≤90 days) and 1644 (>90 days), against Delta 1496 (≤90 days)) and 501 (>90 days), against Omicron 1953 (≤90 days)) and 843 (>90 days).
- D) Inhibition of cell entry of Wuhan D614G (blue symbols), Delta (green symbols) and Omicron (red symbols) spike carrying pseudoparticles by monoclonal antibodies. Increasing doses of Bamlanivimab (triangles), Casirivimab (squares) and Imdevimab (circles) were preincubated with pseudoparticles before addition to cells (doses were titrated in 4-fold dilution from 2000 ng/ml to 0.49 ng/ml (final concentrations on cells)). Infection rates in A-D were determined 16 hours post infection by measuring luciferase activities in cellular lysates. Data shown were derived from one experiment performed in duplicates.



219	
220	
221	Figure 2: Correlation of anti-S antibody concentrations and neutralization capacity against spike variants
222	Correlation matrix of NT50 against Omicron, Wuhan D614G, Delta, and anti-SARS-CoV-2 QuantiVac (IgG) ELISA and Elecsys SARS-CoV-2 based on
223	Spearman Correlation. The dendrogram shows clustering of NT50 against Wuhan D614G and Delta and between anti-SARS-CoV-2-QuantiVac-ELISA (IgG)
224	and Elecsys Anti-SARS-CoV-2 S.
225	

Figure 3:





230

Figure 3: Correlation between anti-S antibody concentrations and NT50 against Delta and Omicron

- 231 A) Correlation between anti-S antibody concentrations measured by anti-SARS-CoV-2-QuantiVac-ELISA (IgG) and NT50 against Omicron (Spearman correlation 0.88). Results of non-vaccinated convalescents (inf) are shown as triangles, and results of vaccinated convalescents (inf + vax) are shown as filled circles.
- 234 **B)** Correlation between anti-S antibody concentrations measured by Elecsys Anti-SARS-CoV-2 S and NT50 against Omicron (Spearman correlation 0.92).

 Results of non-vaccinated convalescents (inf) are shown as triangles, and results of vaccinated convalescents (inf + vax) are shown as filled circles.
- C) Correlation between anti-S antibody concentrations measured by anti-SARS-CoV-2 QuantiVac-ELISA (IgG) and NT50 against Delta (Spearman correlation 0.94). Results of non-vaccinated convalescents (inf) are shown as triangles, and results of vaccinated convalescents (inf + vax) are shown as filled circles.
- Correlation between anti-S antibody concentrations measured by Elecsys Anti-SARS-CoV-2 S and NT50 against Delta (Spearman correlation 0.90). Results of non-vaccinated convalescents (inf) are shown as triangles, and results of vaccinated convalescents (inf + vax) are shown as filled circles.








Figure 4: Receiver operating characteristics analyses of serological assays and neutralization of spike variants

Receiver operating characteristics (ROC) analyses of Elecsys Anti-SARS-CoV-2 S (red lines) and anti-SARS-CoV-2-QuantiVac-ELISA (IgG) (blue lines) prediction of neutralization of Wuhan D614G (panel A), Delta (panel B) and Omicron (panel C). A positive neutralizing titer was arbitrarily defined as ≥640. Area under the curve (AUC) is reported in the graphs, p<0.0001 for all serological assays and all spike variants.

perpetuity. It is made available under a CC-BY 4.0 International license .

248 Reference List

249

258

259

260 261

262

263

264

267

- 250 (1) WHO Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern. https://www who int/news/item/26-11-2021-classification-of-omicron-(b 1 1 529)-sars-cov-2-variant-of-concern 252 2021.
- 253 (2) Libster R, Perez MG, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early High-Titer Plasma 254 Therapy to Prevent Severe Covid-19 in Older Adults. N Engl J Med 2021 Feb 18;384(7):610-8.
- Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N Engl J Med 2021 Mar 18;384(11):1015-27.
 - (4) Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et al. Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG. Am J Pathol 2021 Jan;191(1):90-107.
 - (5) Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, et al. Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma. medRxiv 2021 Jan 1;http://medrxiv.org/content/early/2021/12/21/2021.12.10.21267485:2021.
- de Candia P., Prattichizzo F, Garavelli S, La GR, De RA, Pontarelli A, et al. Effect of time and titer in convalescent plasma therapy for COVID-19. iScience 2021 Aug 20;24(8):102898.
 - (7) Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, et al. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncol 2021 Jun 17;7(8):1167-75.
- 270 (8) Senefeld JW, Klassen SA, Ford SK, Senese KA, Wiggins CC, Bostrom BC, et al. Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion 2021 May 25;61(8):2503-11.
- 272 (9) Hueso T, Godron AS, Lanoy E, Pacanowski J+, Levi LI, Gras E, et al. Convalescent plasma improves 273 overall survival in patients with B-cell lymphoid malignancies and COVID-19: a longitudinal cohort 274 and propensity score analysis. medRxiv 2022 Jan 275 1;http://medrxiv.org/content/early/2022/01/01/2021.12.29.21268525:2021.
- (10) Körper S, Weiss M, Zickler D, Wiesmann T, Zacharowski K, Corman VM, et al. Results of the CAPSID
 randomized trial for high-dose convalescent plasma in patients with severe COVID-19. J Clin Invest
 278 2021 Oct 15;131: e152264(20).
- 279 (11) O'Donnell MR, Grinsztejn B, Cummings MJ, Justman JE, Lamb MR, Eckhardt CM, et al. A 280 randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. 281 J Clin Invest 2021 Jul 1;131: e150646(13).
- 282 (12) Rössler A, Riepler L, Bante D, Laer Dv, Kimpel J. SARS-CoV-2 B.1.1.529 variant (Omicron) evades
 283 neutralization by sera from vaccinated and convalescent individuals. medRxiv 2021 Jan
 284 1;http://medrxiv.org/content/early/2021/12/11/2021.12.08.21267491:2021.
- 285 (13) Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, et al. Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies. medRxiv 2021 Jan 1;http://medrxiv.org/content/early/2021/12/08/2021.12.07.21267432.1:2021.

perpetuity.

It is made available under a CC-BY 4.0 International license .

- 288 (14) Liu L, Iketani S, Guo Y, Chan JF-W, Wang M, Liu L, et al. Striking antibody evasion manifested by 289 the Omicron variant of SARS-CoV-2. Nature 2021;doi: https://doi.org/10.1038/d41586-021-290 03826-3.
- 291 (15) Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, et al. Considerable 292 escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 2021;doi: 293 https://doi.org/10.1038/d41586-021-03827-2.
- 294 (16) Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepeda SK, Culap K, et al. Broadly neutralizing 295 antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 2021;doi: 296 https://doi.org/10.1038/d41586-021-03826-3.
- (17) Körper S, Jahrsdörfer B, Corman VM, Pilch J, Wuchter P, Blasczyk R, et al. Donors for SARS-CoV-2
 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time
 Course of SARS-CoV-2 Neutralizing Antibodies. Transfusion Medicine and Hemotherapy
 2021;48(3):137-47.
- (18) Gross R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D, et al. Heterologous ChAdOx1 nCoV 19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T
 cell reactivity against prevalent SARS-CoV-2 variants. EBioMedicine 2021 Dec 17;75:103761.
- 304 (19) Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally enhanced 305 neutralizing breadth against SARS-CoV-2 one year after infection. Nature 2021 Jul;595(7867):426-306 31.